Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylsalicylic acid + codeine + paracetamol
- Development stage
- Unknown
- Lead developer
- Bioeel
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aspaco is an oral fixed-dose combination drug containing acetylsalicylic acid (aspirin), paracetamol (acetaminophen), and codeine phosphate. Developed and marketed by Bioeel in Romania, it is indicated for the short-term symptomatic relief of mild to moderate pain, including headaches, migraines, toothaches, muscle or joint pain, dysmenorrhea, and febrile conditions. The combination leverages three distinct mechanisms of action: acetylsalicylic acid acts as a non-steroidal anti-inflammatory drug (NSAID) by irreversibly inhibiting cyclooxygenase (COX) enzymes; paracetamol provides additional analgesic and antipyretic effects, likely through central cyclooxygenase inhibition; and codeine acts as a weak opioid receptor agonist to alter the perception of pain. Aspaco is approved and available as an over-the-counter (OTC) medication.
- Brand names
- Aspaco
- Other names
- acetylsalicylic acid + paracetamol + codeineaspirin + codeine + paracetamolaspirin + paracetamol + codeine
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on acetylsalicylic acid + codeine + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylsalicylic acid + codeine + paracetamol.